Skip to content Skip to footer
New Drug Designations - August 2024

New Drug Designations – August 2024 

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. August month’s report includes designations allotted to 10 small molecules, 9 biologics, 7 cell & gene therapies, 1 vaccine, 2 radiopharmaceutical, 1 peptide, 1 antineoplastic and 2 devices  In August 2024, Invenra’s INV724 received the…

Read more

New Drug Designations - May 2024

New Drug Designations – May 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 12 small molecules, 7 biologics, 9 cell & gene therapies, 1 vaccine, 1 peptide, 1 RNA candidate, 1 recombinant fusion protein, 1 imaging agent and 6 devices This…

Read more

thoughtspot_alyssa bladon

What Are The Signs Of A Vaccine Injury?

The signs and symptoms of a potential vaccine injury can vary. They may include symptoms such as severe pain or swelling at the injection site, whole-body rashes or hives, fever, difficulty breathing or swallowing, extreme fatigue, vomiting, or swollen lymph nodes.Other adverse reactions that could be attributed to a vaccine injury include neurological disorders…

Read more

Viewpoints_Yoshio Okubo

Yoshio Okubo, Senior Director, Head of Pandemic Global Product Team for Takeda Shares Insights on the Approval of its Covid-19 Vaccine

Shots:Yoshio spoke about the approval of the Nuvaxovid COVID-19 Vaccine for Primary and Booster Immunization in Japan. Nuvaxovid Intramuscular Injection is the first recombinant protein-based COVID-19 vaccine approved for use in JapanYoshio also talked about Takeda’s collaboration with Novavax for the development, manufacturing, and commercialization of Nuvaxovid in JapanFurther, the interview highlighted…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]